Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for ERIS.BO and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ERIS.BO and 80,000+ other tickers.
See exactly how ERIS.BO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ERIS.BO and 80,000+ other tickers.
Eris Lifesciences Ltd., along with its affiliated companies, operates in India, specializing in the production, promotion, and supply of proprietary pharmaceutical drugs aimed at treating chronic and semi-chronic health conditions. The company's extensive product portfolio encompasses a wide array of branded formulations across numerous therapeutic categories, including treatments for diabetes, infections, cardiovascular ailments, dermatological issues, digestive disorders, blood-related conditions, hormonal imbalances, central nervous system disorders, neuropsychiatric conditions, ear…
No recent news available.